Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study

Overview

Journal Indian J Surg Oncol

Specialty Oncology

Date 2021 May 17

PMID 33994736

Authors

Pushkar Chandra

Ruhi Dixit

Arvind Pratap

Suman Mishra

Rajnikant Mishra

Vijay Kumar Shukla

Affiliations

Soon will be listed here.

Abstract

The Suvar, Enhancer of zeste, and Trithorax (SET) and myeloid-Nervy-DEAF-1 (MYND) domain-containing protein 3 (SMYD3) is a histone lysine methyltransferase and has been recently unveiled to play significant roles in the progression of human cancer via regulating various key cancer-associated genes and pathways. The role of SMYD3 in gallbladder cancer (GBC) still needs to be studied. In the present study, we examined the SMYD3 gene expression at mRNA and protein level to look its impact on risk for developing gallbladder carcinogenesis. SMYD3 expression was evaluated by immunohistochemistry and reverse transcriptase PCR (RT-PCR) from 30 cases each of GBC and cholelithiasis patients. The expression was compared with different clinicopathological parameters. The SMYD3 expression was found to be significantly upregulated in GBC than cholelithiasis group ( < 0.05). The SMYD3 with increased expression level was observed in 73.3% of the GBC cases ( < 0.05). Moreover, mRNA SMYD3 expression was observed in 73.3% of GBC and 10% of control ( < 0.05). Our results indicated that the overexpression of SMYD3 plays an important role in the GBC progression, and SMYD3 may represent useful biomarker for gallbladder cancer patients.

References

Liu Y, Luo X, Deng J, Pan Y, Zhang L, Liang H . SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma. Tumour Biol. 2014; 36(4):2685-94. DOI: 10.1007/s13277-014-2891-z. View

Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y . Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy. Tumour Biol. 2015; 37(6):7371-81. DOI: 10.1007/s13277-015-4410-2. View

Dai B, Wan W, Zhang P, Zhang Y, Pan C, Meng G . SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity. Oncol Rep. 2015; 34(5):2722-30. DOI: 10.3892/or.2015.4239. View

Peserico A, Germani A, Sanese P, Barbosa A, Di Virgilio V, Fittipaldi R . A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth. J Cell Physiol. 2015; 230(10):2447-2460. PMC: 4988495. DOI: 10.1002/jcp.24975. View

Van Aller G, Reynoird N, Barbash O, Huddleston M, Liu S, Zmoos A . Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics. 2012; 7(4):340-3. PMC: 3368817. DOI: 10.4161/epi.19506. View

Zhu Y, Zhu M, Zhang X, Xu X, Wu Z, Liao L . SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma. Hum Pathol. 2016; 52:153-63. DOI: 10.1016/j.humpath.2016.01.012. View

Hundal R, Shaffer E . Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014; 6:99-109. PMC: 3952897. DOI: 10.2147/CLEP.S37357. View

Giakountis A, Moulos P, Sarris M, Hatzis P, Talianidis I . Smyd3-associated regulatory pathways in cancer. Semin Cancer Biol. 2016; 42:70-80. DOI: 10.1016/j.semcancer.2016.08.008. View

Shukla V, Khandelwal C, Roy S, VAIDYA M . Primary carcinoma of the gall bladder: a review of a 16-year period at the University Hospital. J Surg Oncol. 1985; 28(1):32-5. DOI: 10.1002/jso.2930280109. View

10.

Furuta M, Kozaki K, Tanaka S, Arii S, Imoto I, Inazawa J . miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2009; 31(5):766-76. DOI: 10.1093/carcin/bgp250. View

11.

Sims 3rd R, Reinberg D . From chromatin to cancer: a new histone lysine methyltransferase enters the mix. Nat Cell Biol. 2004; 6(8):685-7. DOI: 10.1038/ncb0804-685. View

12.

He C, Xu J, Zhang J, Xie D, Ye H, Xiao Z . High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol. 2012; 43(9):1425-35. DOI: 10.1016/j.humpath.2011.11.003. View

13.

Luo X, Zhang C, Zhao W, Liu Z, Liu L, Mu A . Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells. Cancer Lett. 2013; 344(1):129-137. DOI: 10.1016/j.canlet.2013.10.026. View

14.

Sponziello M, Durante C, Boichard A, Dima M, Puppin C, Verrienti A . Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. Mol Cell Endocrinol. 2014; 392(1-2):8-13. DOI: 10.1016/j.mce.2014.04.016. View

15.

Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva F, Li M . SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004; 6(8):731-40. DOI: 10.1038/ncb1151. View

16.

Zhu C, Huang Q . Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer. Dig Dis Sci. 2019; 65(2):489-499. DOI: 10.1007/s10620-019-05797-y. View

17.

Moulos P, Sarris M, Talianidis I . Mechanism of gene-specificity of oncogenic regulators. Cell Cycle. 2016; 15(17):2227-8. PMC: 5004681. DOI: 10.1080/15384101.2016.1191254. View

18.

Dwivedi A, Jain S, Dixit R . Gall bladder carcinoma: Aggressive malignancy with protean loco-regional and distant spread. World J Clin Cases. 2015; 3(3):231-44. PMC: 4360495. DOI: 10.12998/wjcc.v3.i3.231. View

19.

Hamamoto R, Silva F, Tsuge M, Nishidate T, Katagiri T, Nakamura Y . Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006; 97(2):113-8. PMC: 11159510. DOI: 10.1111/j.1349-7006.2006.00146.x. View

20.

Rakic M, Patrlj L, Kopljar M, Klicek R, Kolovrat M, Loncar B . Gallbladder cancer. Hepatobiliary Surg Nutr. 2014; 3(5):221-6. PMC: 4207839. DOI: 10.3978/j.issn.2304-3881.2014.09.03. View